Abstract Number: 2652 • 2018 ACR/ARHP Annual Meeting
Engaging the Cholinergic Anti-Inflammatory Pathway By Stimulating the Vagus Nerve Reduces Pain and Fatigue in Patients with SLE
Background/Purpose: Musculoskeletal (MS) pain is a common symptom of patients with Systemic Lupus Erythematosus (SLE) affecting up to 95% of patients and contributing to…Abstract Number: 2653 • 2018 ACR/ARHP Annual Meeting
Contraceptive Documentation in Systemic Lupus Erythematosus Patients at a Safety Net Hospital
Background/Purpose: Systemic Lupus Erythematosus (SLE) predominately affects reproductive aged women. Contraceptive counseling is an important quality indicator in SLE patient care. Here we evaluate current…Abstract Number: 2654 • 2018 ACR/ARHP Annual Meeting
Exposure to Air Pollution and the Onset and Progression of Systemic Lupus Erythematosus
Background/Purpose: Air pollution may contribute to many autoimmune diseases including systemic lupus erythematosus (SLE), but limited information is available on its role in the onset…Abstract Number: 2655 • 2018 ACR/ARHP Annual Meeting
SLE-Key® Ruleout Testing in Support of Patient Triage in the Clinical Rheumatology Setting
Background/Purpose: SLE diagnosis and classification can be challenging. The low incidence of SLE limits primary care physician experience with the disease, but the impact of…Abstract Number: 2656 • 2018 ACR/ARHP Annual Meeting
Apremilast As Treatment of Refractory Skin Lupus Lesions
Background/Purpose: Skin lesions of lupus may be refractory to standard therapy. Apremilast is an orally small molecule which inhibits phosphodiesterase-4 (PDE-4) that modulates some inflammatory…Abstract Number: 2657 • 2018 ACR/ARHP Annual Meeting
Assessment of Habitual Physical Activity and Performance during Maximal Exercise Test in Systemic Lupus Erythematosus Patients
Background/Purpose: Patients with systemic lupus erythematosus (SLE) present low physical capacity when compared to healthy controls. In addition to chronotropic incompetence during exercise, slow recovery…Abstract Number: 2658 • 2018 ACR/ARHP Annual Meeting
Real World Medication Use in Incident Systemic Lupus Erythematosus and Lupus Nephritis Patients
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that causes inflammation in connective tissues and can involve multiple organs systems. Lupus nephritis (LN) is…Abstract Number: 2659 • 2018 ACR/ARHP Annual Meeting
Clinical Features, Damage Accrual and Survival in Patients with Familial Systemic Lupus Erythematosus (SLE): Data from a Multiethnic, Multinational Latin American Lupus Cohort
Background/Purpose: GLADEL (Grupo Latino Americano De Estudio de Lupus) has previously shown that a 14.1% of its patients have relatives with an autoimmune disease (1).…Abstract Number: 2660 • 2018 ACR/ARHP Annual Meeting
Low-Dose Interleukin-2 Treatment of Refractory Lupus Nephritis
Background/Purpose: Lupus nephritis (LN) is a common and serious organ manifestation of SLE and is associated with substantial patient morbidity and mortality. The production of…Abstract Number: 2661 • 2018 ACR/ARHP Annual Meeting
Metformin Combined with Conventional Therapy Increases Absolute Number of Regulatory T Cells in Patients with Systemic Lupus Erythematosus
Background/Purpose:To observe the clinical efficacy of metformin in the treatment of SLE and regulation of CD4+ Treg and Th17 cells.Methods:Thirty-one patients with SLE, fulfilled the ACR…Abstract Number: 2662 • 2018 ACR/ARHP Annual Meeting
Changes in Blood Pressure and Proteinuria at One Year in Two Lupus Nephritis Clinical Trials
Background/Purpose: Hypertension predicts poor long-term renal outcomes for patients with lupus nephritis (LN) [1, 2]. We sought to characterize relationships between blood pressure and proteinuria…Abstract Number: 2663 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical and Laboratory Profiles in 3575 Systemic Lupus Erythematosus Patients with and without Sjögren’s Syndrome: Data from the Spanish Society for Rheumatology Lupus Registry
Background/Purpose: The clinical coexistence of Systemic Lupus Erythematosus (SLE) and Sjögren's Syndrome (SS) was recognized in 1959. The prevalence of SS among patients with SLE…Abstract Number: 2664 • 2018 ACR/ARHP Annual Meeting
Long-Term Clinical Outcomes in a Cohort of Adults with Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: Childhood-onset SLE (cSLE) is a severe lifelong multisystem autoimmune disease. Long-term outcome data are limited. Here, we report for the first time on the…Abstract Number: 2665 • 2018 ACR/ARHP Annual Meeting
Treatment Trends of Systemic Lupus Erythematosus during Early-Years of the Disease
Background/Purpose: Systemic lupus erythematosus (SLE) is treated with glucocorticoids, anti-malarials, immunosuppressive medications, and, more recently, biologics (specifically, belimumab and rituximab). While belimumab had positive results…Abstract Number: 2666 • 2018 ACR/ARHP Annual Meeting
Trends in Treatment of Systemic Lupus Erythematosus and Lupus Nephritis: 2006-2016
Background/Purpose: Glucocorticoids, anti-malarials and conventional immunosuppressive agents have been the mainstay of therapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN); more recently biologic…
ACR Meeting Abstracts